A Director at Vertex Pharmaceuticals (VRTX) is Buying Shares

Today, a Director at Vertex Pharmaceuticals (VRTX), Margaret Mcglynn, bought shares of VRTX for $815.4K.

Following this transaction Margaret Mcglynn’s holding in the company was increased by 242.48% to a total of $740.4K. Following Margaret Mcglynn’s last VRTX Buy transaction on April 08, 2015, the stock climbed by 55.7%.

See today’s analyst top recommended stocks >>

Based on Vertex Pharmaceuticals’ latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $933 million and quarterly net profit of $267 million. In comparison, last year the company earned revenue of $755 million and had a net profit of $207 million. The company has a one-year high of $195.81 and a one-year low of $151.80. VRTX’s market cap is $46.15B and the company has a P/E ratio of 21.05.

10 different firms, including BMO Capital and Citigroup, currently also have a Buy rating on the stock.

The insider sentiment on Vertex Pharmaceuticals has been positive according to 106 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts